BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Elbion AG Partners with Oakwood Laboratories for Sustained Release Naltrexone Treatment for Alcohol Dependence


1/15/2008 1:04:42 PM

Leuven, Belgium ... elbion NV, a European specialty pharmaceutical company with a focus on neurology and immunology, today announced that it has entered a collaboration agreement with Oakwood Laboratories, L.L.C for manufacturing of its Naltrexone Depot sustained release product for alcohol dependence.

Oakwood Laboratories of Oakwood Village (near Cleveland), Ohio, USA is a privately held company specializing in the development and manufacture of controlled release injectable pharmaceutical formulations.

elbion ´s Naltrexone Depot is designed as a monthly intramuscular injection. elbion believes the formulation has significant advantages over conventional naltrexone products, for which treatment compliance is a major limiting factor. Previous clinical trials with Naltrexone Depot have shown encouraging results with a trend towards greater levels of abstinence for patients receiving treatment compared to those on placebo.

Bernd Kastler, CEO of elbion, commented: “We expect this agreement to expedite the completion of development of this advanced clinical product, which we believe can be a significant value driver for elbion. Alcohol dependence has a profound effect on the lives of millions of people around the world and we believe that Naltrexone Depot has the potential to play a major role in their treatment. We are very impressed with Oakwood’s capabilities, and find them to be a premier service provider in this particular field.”

Mark Smith, President of Oakwood said, “We are pleased to enter into this collaboration with elbion, and its dynamic and experienced management team. We believe that Oakwood’s ability to provide rapid formulation development and refinement, as well as scale up and clinical and commercial manufacture, will bring this project to a successful conclusion.”

View the full press release: http://www.elbion.com/pdf/elbion_Oakwood_Jan08_ENG.pdf

elbion NV Halvestraat 3 3000 Leuven Belgium

phone: +32 (0)476 93 45 79 www.elbion.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES